This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
Niesen and Shah describe an infant with microcephaly and a range of dysmorphic features whose mother had been treated with high doses of pyridostigmine bromide (PB).1 Although there is no question that PB was administered well beyond recommended doses, we believe the conclusion that pyridostigmine induced microcephaly be viewed with caution. As the authors point out in the text of their paper, this was an association of PB overuse and the infant’s congenital defects. Also, there is little support from this single report that toxicity is dose-dependent.
There is scant evidence from animal studies to suggest that birth defects occur with PB exposure. Rats and rabbits administered 50 to 93 times the typical human dose of PB during pregnancy demonstrate no adverse effects on pregnancy, litter size, malformation rate, or fetal development.2 Injection of chick embryos with cholinesterase inhibitors, including PB, leads to abnormalities of the vertebral column and hypoplasia of leg muscles, but not the microcephaly observed in the infant in this case report.2 The authors cite the study of Levine and Parker3 that found rat pups exposed to PB had abnormal ossification of cervical vertebrae, but only at the highest doses tested. These authors conclude that the “slight increase in ossification …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
